Ventyx Biosciences, Inc. (VTYX)
After hours:
| Previous close | 4.2400 |
| Open | 4.1500 |
| Bid | 4.0300 x 100 |
| Ask | 4.0900 x 200 |
| Day's range | 3.9400 - 4.1500 |
| 52-week range | 1.8650 - 40.5800 |
| Volume | |
| Avg. volume | 4,024,772 |
| Market cap | 286.227M |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.3000 |
| Earnings date | 25 Mar 2024 - 29 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.80 |
GlobeNewswireVentyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a pa
- GlobeNewswire
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share in a private placement to certain qualified institutional buyers and ins
- GlobeNewswire
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: Jefferies Biotech on the Bay SummitLocation: Miami, FL Date: Wednesday, March 13, 2024 Event: Barclays 26th Annual G
